Description and Brand Names
Información sobre medicamentos proporcionada por: IBM Micromedex
US Brand Name
- Kymriah
Descriptions
Tisagenlecleucel injection is used to treat B-cell acute lymphoblastic leukemia (ALL) that has come back a second or later time or after other medicines did not work well in patients up to 25 years of age. Leukemia is a type of cancer where the body makes abnormal white blood cells.
Tisagenlecleucel injection is also used to treat diffuse large B-cell lymphoma (DLBCL) that has come back a second or later time or after at least 2 other medicines did not work well. Lymphoma is a type of cancer where the body makes abnormal white blood cells.
Tisagenlecleucel injection is an antineoplastic (cancer) medicine that is made from your own white blood cells. These cells are reprogrammed to contain a chimeric antigen receptor (CAR) to identify the cancer cells from the normal cells and kill them. Before you begin treatment, talk to your doctor about the benefits of this medicine as well as the possible risks of receiving it.
This medicine is available only under a restricted distribution program called Kymriah® REMS (Risk Evaluation and Mitigation Strategy) Program.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2020
Copyright © 2020 IBM Watson Health. Todos los derechos reservados. La información es de uso exclusivo para usuarios finales y se prohíbe su venta, redistribución o uso con fines comerciales.